Literature DB >> 14643972

Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs.

Y V Rama Prasad1, Sudarat Eaimtrakarn, Makoto Ishida, Yoichi Kusawake, Riichi Tawa, Yukako Yoshikawa, Nobuhito Shibata, Kanji Takada.   

Abstract

Gentamicin (GM) is a polarized water-soluble compound having very poor intestinal membrane permeability resulting in low oral bioavailability. Labrasol was found to improve the intestinal absorption of GM in rats. In the present study, GM formulations containing labrasol were evaluated in beagle dogs after filling into hydroxypropylmethyl cellulose (HPMC) capsules wrapped with Eudragit L100 (Eud L) and Eudragit S100 (Eud S) films. The results of the in vitro drug release studies could not differentiate between two kinds of enteric capsules and among the three kinds of GM formulations. Oral administration of GM solution at a dose of 50.0 mg per dog of GM and 0.60 ml per dog of labrasol has resulted in Cmax values of 2.38 +/- 0.50 microg/ml and 2.30 +/- 0.42 microg/ml with Eud L and Eud S capsules, respectively. The AUC values obtained were also higher at 4.35 +/- 1.31 microg h/ml and 5.34 +/- 0.95 microg h/ml with Eud L and Eud S capsules, respectively. Formulation of GM as a suspension in labrasol has resulted in the decrease of Cmax values by two to four times and AUC values by > 2.5 times compared to the solution formulation. The above results indicate that solution formulation was better over the suspension. An absorbent, synthetic sponge was used to absorb GM solution formulation and encapsulated with Eud L and Eud S capsules. The Cmax and AUC values obtained with sponge formulation were higher than those of suspension formulations but were lower than solution formulations. There was no significant difference in the extent of GM absorption between Eud L and Eud S capsules used for encapsulating GM formulations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643972     DOI: 10.1016/j.ijpharm.2003.08.008

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Influence of formulation factors on tablet formulations with liquid permeation enhancer using factorial design.

Authors:  Naveen K Bejugam; Helen J Parish; Gita N Shankar
Journal:  AAPS PharmSciTech       Date:  2009-12-01       Impact factor: 3.246

2.  Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Authors:  Anna Kruczynski; Isabelle Vandenberghe; Arnaud Pillon; Sabrina Pesnel; Liliane Goetsch; Jean-Marc Barret; Yves Guminski; Alain Le Pape; Thierry Imbert; Christian Bailly; Nicolas Guilbaud
Journal:  Invest New Drugs       Date:  2009-09-24       Impact factor: 3.850

3.  Formulation and cytotoxicity evaluation of new self-emulsifying multiple W/O/W nanoemulsions.

Authors:  Estelle Sigward; Nathalie Mignet; Patrice Rat; Mélody Dutot; Saleh Muhamed; Jean-Michel Guigner; Daniel Scherman; Denis Brossard; Sylvie Crauste-Manciet
Journal:  Int J Nanomedicine       Date:  2013-02-07

4.  Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.

Authors:  Petra Obioma Nnamani; Agatha Adaora Ugwu; Emmanuel Chinedu Ibezim; Franklin Chimaobi Kenechukwu; Paul Achile Akpa; John-Dike Nwabueze Ogbonna; Nicholas Chinedu Obitte; Amelia Ngozi Odo; Maike Windbergs; Claus-Michael Lehr; Anthony Amaechi Attama
Journal:  Int J Nanomedicine       Date:  2016-11-28

5.  The Synergistic Antibacterial Mechanism of Gentamicin-Loaded CaCO 3 Nanoparticles.

Authors:  Xiaohong Pan; Saili Chen; Dongzhe Li; Wenhua Rao; Yilin Zheng; Zhaoyuan Yang; Lan Li; Xiong Guan; Zhi Chen
Journal:  Front Chem       Date:  2018-01-23       Impact factor: 5.221

6.  Effects of spray-drying and choice of solid carriers on concentrations of Labrasol® and Transcutol® in solid self-microemulsifying drug delivery systems (SMEDDS).

Authors:  Liang Li; Tao Yi; Christopher Wai-Kei Lam
Journal:  Molecules       Date:  2013-01-02       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.